Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer

Min Che Tung, Chin Shaw Stella Tsai, Jai Nien Tung, Tang Yi Tsao, Hung Chang Chen, Kun Tu Yeh, Ching Fong Liao, Ming Chung Jiang

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Metastatic markers are highly useful diagnostic and prognostic indicators of cancer metastasis. Herein, we report that secretory CSE1L/CAS, a cellular apoptosis susceptibility protein, is a new marker for metastatic cancer. CAS was colocalized with matrix metalloproteinase-2 in vesicles surrounding the outside of MCF-7 cell membranes, and the COOH-terminal domain of CAS was associated with matrix metalloproteinase-2-containing vesicles. Immunohistochemical staining for CAS was positive in the stroma and gland lumens of human metastatic cancer tissues. CAS was also detected in conditioned medium from B16-F10 melanoma cells and more frequently in the sera of patients with metastatic cancer than in sera from patients with primary cancer. Specifically, the prevalence of serum CAS in serum samples from 146 patients was 58.2% (32 of 55), 32.0% (8 of 25), and 12.1% (8 of 66) for patients with metastatic, invasive, and primary cancers, respectively. Our results suggest that CAS is a secretory protein associated with cancer metastasis, which may have clinical utility in metastatic cancer screening and diagnosis.

Original languageEnglish
Pages (from-to)1570-1577
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume18
Issue number5
DOIs
Publication statusPublished - May 2009

Fingerprint

Serum
Neoplasms
Matrix Metalloproteinase 2
Cellular Apoptosis Susceptibility Protein
Neoplasm Metastasis
Experimental Melanomas
MCF-7 Cells
Conditioned Culture Medium
Early Detection of Cancer
Cell Membrane
Staining and Labeling
Proteins

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Tung, M. C., Tsai, C. S. S., Tung, J. N., Tsao, T. Y., Chen, H. C., Yeh, K. T., ... Jiang, M. C. (2009). Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer. Cancer Epidemiology Biomarkers and Prevention, 18(5), 1570-1577. https://doi.org/10.1158/1055-9965.EPI-08-0948

Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer. / Tung, Min Che; Tsai, Chin Shaw Stella; Tung, Jai Nien; Tsao, Tang Yi; Chen, Hung Chang; Yeh, Kun Tu; Liao, Ching Fong; Jiang, Ming Chung.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 18, No. 5, 05.2009, p. 1570-1577.

Research output: Contribution to journalArticle

Tung, MC, Tsai, CSS, Tung, JN, Tsao, TY, Chen, HC, Yeh, KT, Liao, CF & Jiang, MC 2009, 'Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 5, pp. 1570-1577. https://doi.org/10.1158/1055-9965.EPI-08-0948
Tung, Min Che ; Tsai, Chin Shaw Stella ; Tung, Jai Nien ; Tsao, Tang Yi ; Chen, Hung Chang ; Yeh, Kun Tu ; Liao, Ching Fong ; Jiang, Ming Chung. / Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2009 ; Vol. 18, No. 5. pp. 1570-1577.
@article{2b60976d682248d48cd841279cb85a18,
title = "Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer",
abstract = "Metastatic markers are highly useful diagnostic and prognostic indicators of cancer metastasis. Herein, we report that secretory CSE1L/CAS, a cellular apoptosis susceptibility protein, is a new marker for metastatic cancer. CAS was colocalized with matrix metalloproteinase-2 in vesicles surrounding the outside of MCF-7 cell membranes, and the COOH-terminal domain of CAS was associated with matrix metalloproteinase-2-containing vesicles. Immunohistochemical staining for CAS was positive in the stroma and gland lumens of human metastatic cancer tissues. CAS was also detected in conditioned medium from B16-F10 melanoma cells and more frequently in the sera of patients with metastatic cancer than in sera from patients with primary cancer. Specifically, the prevalence of serum CAS in serum samples from 146 patients was 58.2{\%} (32 of 55), 32.0{\%} (8 of 25), and 12.1{\%} (8 of 66) for patients with metastatic, invasive, and primary cancers, respectively. Our results suggest that CAS is a secretory protein associated with cancer metastasis, which may have clinical utility in metastatic cancer screening and diagnosis.",
author = "Tung, {Min Che} and Tsai, {Chin Shaw Stella} and Tung, {Jai Nien} and Tsao, {Tang Yi} and Chen, {Hung Chang} and Yeh, {Kun Tu} and Liao, {Ching Fong} and Jiang, {Ming Chung}",
year = "2009",
month = "5",
doi = "10.1158/1055-9965.EPI-08-0948",
language = "English",
volume = "18",
pages = "1570--1577",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer

AU - Tung, Min Che

AU - Tsai, Chin Shaw Stella

AU - Tung, Jai Nien

AU - Tsao, Tang Yi

AU - Chen, Hung Chang

AU - Yeh, Kun Tu

AU - Liao, Ching Fong

AU - Jiang, Ming Chung

PY - 2009/5

Y1 - 2009/5

N2 - Metastatic markers are highly useful diagnostic and prognostic indicators of cancer metastasis. Herein, we report that secretory CSE1L/CAS, a cellular apoptosis susceptibility protein, is a new marker for metastatic cancer. CAS was colocalized with matrix metalloproteinase-2 in vesicles surrounding the outside of MCF-7 cell membranes, and the COOH-terminal domain of CAS was associated with matrix metalloproteinase-2-containing vesicles. Immunohistochemical staining for CAS was positive in the stroma and gland lumens of human metastatic cancer tissues. CAS was also detected in conditioned medium from B16-F10 melanoma cells and more frequently in the sera of patients with metastatic cancer than in sera from patients with primary cancer. Specifically, the prevalence of serum CAS in serum samples from 146 patients was 58.2% (32 of 55), 32.0% (8 of 25), and 12.1% (8 of 66) for patients with metastatic, invasive, and primary cancers, respectively. Our results suggest that CAS is a secretory protein associated with cancer metastasis, which may have clinical utility in metastatic cancer screening and diagnosis.

AB - Metastatic markers are highly useful diagnostic and prognostic indicators of cancer metastasis. Herein, we report that secretory CSE1L/CAS, a cellular apoptosis susceptibility protein, is a new marker for metastatic cancer. CAS was colocalized with matrix metalloproteinase-2 in vesicles surrounding the outside of MCF-7 cell membranes, and the COOH-terminal domain of CAS was associated with matrix metalloproteinase-2-containing vesicles. Immunohistochemical staining for CAS was positive in the stroma and gland lumens of human metastatic cancer tissues. CAS was also detected in conditioned medium from B16-F10 melanoma cells and more frequently in the sera of patients with metastatic cancer than in sera from patients with primary cancer. Specifically, the prevalence of serum CAS in serum samples from 146 patients was 58.2% (32 of 55), 32.0% (8 of 25), and 12.1% (8 of 66) for patients with metastatic, invasive, and primary cancers, respectively. Our results suggest that CAS is a secretory protein associated with cancer metastasis, which may have clinical utility in metastatic cancer screening and diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=66549089442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66549089442&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-08-0948

DO - 10.1158/1055-9965.EPI-08-0948

M3 - Article

VL - 18

SP - 1570

EP - 1577

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 5

ER -